跳至主要内容
临床试验/NCT07798128
NCT07798128尚未招募不适用

An Observational, Multinational, In Hospital Evaluation of Catheter Utilization Rates in Female Patients Using Indwelling Urinary Catheters and the PureWick™ Flex Female External Catheter Across Europe and the Middle East

Becton, Dickinson and Company0 个研究点目标入组 240 人开始时间: 2026年11月6日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
尚未招募
入组人数
240
主要终点
Indwelling Urinary Catheter (IUC) Utilization Rate

研究概览

简要总结

Urinary catheterization is commonly used in hospitalized patients for the management of urinary incontinence, immobilization, and monitoring of urinary output. However, indwelling urinary catheters (IUCs) are associated with clinically significant risks, including catheter-associated urinary tract infections (CAUTIs), other infectious and non-infectious complications, prolonged hospital stay, and increased healthcare costs. The risk of complications increases with the duration of catheterization, highlighting the need for strategies to reduce unnecessary catheter use and minimize catheter dwell time.

The PureWick™ Female External Catheter (FFEC) is a non-invasive urine collection device designed to manage urinary incontinence in female patients without the need for an indwelling catheter. By providing an alternative approach to urinary management, it has the potential to reduce reliance on IUCs and associated complications while improving patient comfort and quality of care.

This study is a prospective, multinational, observational, sequential two-cohort study conducted in hospitalized adult female patients across Europe and the Middle East. The study aims to evaluate the effect of introducing the PureWick™ FFEC into clinical practice on indwelling urinary catheter utilization rates in routine hospital care.

Approximately 240 adult female patients requiring urinary management for incontinence during hospitalization will be enrolled across multiple clinical sites. The study consists of two sequential cohorts within participating sites. In Cohort 1, patients will receive standard care using indwelling urinary catheters only. In Cohort 2, following the introduction of the PureWick™ FFEC, patients will be managed using either the external catheter alone or in combination with indwelling catheters, according to routine clinical practice.

The primary objective is to compare indwelling urinary catheter utilization rates before and after the introduction of the PureWick™ FFEC. Catheter utilization is defined as the proportion of inpatient days during which an indwelling catheter is used (catheter-days per patient-days).

Secondary objectives include assessment of the occurrence and nature of adverse events, including urinary tract infections, catheter-associated urinary tract infections, incontinence-associated dermatitis, and falls, as well as evaluation of hospital length of stay. Exploratory objectives include assessment of patient and healthcare professional experience, device usability and satisfaction, pain and discomfort, and sleep quality.

Participants will be followed from enrollment until hospital discharge or up to 40 days, whichever occurs first. The results of this study are intended to provide real-world evidence on urinary catheter utilization patterns and to inform clinical practice regarding the role of non-invasive urinary management strategies in hospitalized female patients.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Adult female subjects ≥ 18 years of age at the time of signing the informed consent.
  • Requiring treatment with indwelling urinary catheters or PureWick™ Flex Female External Catheter (PureWick™ FFEC) for urinary management, including urinary incontinence for at least 3 days after enrollment.
  • Has limited mobility and is not able to use sanitary devices that facilitate controlled bladder emptying like bedpans, commode chairs, voiding at the toilet
  • The expected length of stay from enrollment to hospital discharge is at minimum 10 days
  • Willing to comply with all study procedures in this protocol
  • The subject must be willing and able to read, understand, sign, and date the informed consent form.

排除标准

  • Clinically confirmed urinary retention.
  • Requiring precise urine output measurement
  • Is known to be pregnant at time of enrollment
  • Has a confirmed diagnosis of a urinary tract infection (UTI), catheter-associated urinary tract infection (CAUTI), or sepsis at the time of the planned indwelling urinary catheter implantation
  • Has documented colonization or infection with multidrug-resistant organisms (MDROs) at the time of the planned indwelling urinary catheter implantation
  • Is agitated, combative, and/or uncooperative and may remove the catheter
  • Has any pre-existing neurological, psychiatric, or other conditions that would confound quality of life assessment or would make it difficult to self-report on quality-of-life questionnaires in the opinion of the investigator
  • Has any other condition that, in the opinion of the investigator, would preclude them from participating in the study.
  • Additional Exclusion Criteria (Cohort 2 only - PureWick™ FFEC):
  • Has frequent episodes of bowel incontinence without a fecal management system in place
  • Has moderate to heavy menstruation and cannot use a tampon or menstrual cup
  • Has vaginal or other chronic non-urinary tract infections (UTIs), active genital herpes
  • Has any clinically relevant skin condition (e.g. wound, lesion or irritation) affecting the genital, perineal, or sacral area that could interfere with safe and effective device use where is in contact with the device.

研究组 & 干预措施

Standard of Care (Indwelling Urinary Catheter)

Participants managed for urinary incontinence using indwelling urinary catheters only, in accordance with routine clinical practice.

干预措施: Indwelling Urinary Catheter (IUC) (Device)

PureWick™ Flex Female External Catheter (FFEC) Implementation

Participants managed for urinary incontinence following the introduction of the PureWick™ Female External Catheter, using either the external catheter alone or in combination with indwelling urinary catheters, in accordance with routine clinical practice.

干预措施: PureWick™ Flex Female External Catheter (FFEC) (Device)

PureWick™ Flex Female External Catheter (FFEC) Implementation

Participants managed for urinary incontinence following the introduction of the PureWick™ Female External Catheter, using either the external catheter alone or in combination with indwelling urinary catheters, in accordance with routine clinical practice.

干预措施: Indwelling Urinary Catheter (IUC) (Device)

结局指标

主要结局

Indwelling Urinary Catheter (IUC) Utilization Rate

时间窗: From enrollment (informed consent) until hospital discharge or up to 40 days, whichever occurs first

The proportion of inpatient days during which an indwelling urinary catheter is used, defined as the number of catheter-days divided by the total number of patient-days.

次要结局

  • Occurrence of Adverse Events (AEs)(From enrollment until hospital discharge or up to 40 days)
  • Length of Hospital Stay (LOS)(From enrollment until discharge or up to 40 days)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验